Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
AbbVie Inc.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-71.1% vs price
Base Case (Median)
-56.4% vs price
Bull Case (75th pct.)
-41.0% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| PE Comparable | $79.44 | -69.7% | Medium (25%) |
| EV/EBITDA | $65.35 | -75.1% | Medium (20%) |
| EV/FCF | $171.57 | -34.6% | Medium (20%) |
| Earnings Power Value | $149.49 | -43.1% | Medium (50%) |
Based on 4 out of 7 methods, ABBV appears overvalued at the current price of $262.51. The base case fair value of $114.47 implies 56.4% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.